|
Status
|
Topic selection
|
|
Technology type
|
Medicine
|
|
Decision
|
Not selected
|
|
Reason for decision
|
Not eligible for Health Technology Evaluation guidance
|
|
Further information
|
Decision makers have concluded that a new technology appraisal is not necessary for this licence extension. The guidance in development for Efgartigimod for treating generalised myasthenia gravis [ID4003] will consider the sub-cut formulation, but there will not be a specific recommendation on it, as per standard NICE practice. Please see Section 6.2.1 of the Topic Selection Manual states that: Medicines that meet the eligibility criteria will be selected, except when there is a clear rationale not to do so. For example, when: changes to the dose, formulation or administration will not significantly affect the clinical and cost effectiveness of the medicine.
|
| ID number |
11835
|
Project Team
| Project lead |
Abigail Stephens |
Email enquiries
For further information on how we select topics for development, please see our page about topic selection